475094-55-4

Upstream product

• 475272-04-9 2-(3-isobutyl-4-methoxyphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 475272-16-3 3-benzyl-4-methoxy-benzene-1-boronic acid 
• 434300-54-6 4-(2-cyanoethyl)-2-isobutylphenyl trifluoromethanesulfonate 
• 475272-34-5 3-(3'-benzyl-2,3''-4''-hydroxy-diisobutyl-1,1':4',1''-terphenyl-4-yl)propanenitrile 
• 475272-33-4 3-(3'-benzyl-2,3''-diisobutyl-4''-methoxy-1,1':4',1''-terphenyl-4-yl)propanenitrile 
• 475272-20-9 trifluoro-methanesulfonic acid 3-benzyl-4'-(2-cyanoethyl)-2'-isobutyl-biphenyl-4-yl ester 
• 475272-19-6 3-(3'-benzyl-4'-hydroxy-2-isobutyl-1,1'-biphenyl-4-yl)propanenitrile 
• 475272-18-5 3-(3'-benzyl-2-isobutyl-4'-methoxy-1,1'-biphenyl-4-yl)propanenitrile 
• 475272-35-6 3-(3'-benzyl-4''-(cyanomethoxy)-2,3''-diisobutyl-1,1':4',1''-terphenyl-4-yl)propanenitrile 

Relevant academic research and scientific papers

Development of a potent Bcl-xL antagonist based on α-helix mimicry

The rational design of low-molecular weight ligands that disrupt protein-protein interactions is still a challenging goal in medicinal chemistry. Our approach to this problem involves the design of molecular scaffolds that mimic the surface functionality